Reported 10 months ago
Biotech sector welcomes a new player as Anji Biotechnology (7754) is set to debut on the emerging stock market at 45 yuan per share on the 25th. Anji's Chairman, Huang Wenying, revealed that their fastest-progressing new drug is the authorized rare disease drug AJ201, currently in phase Ib/IIa clinical trials in the U.S., with unblinding expected in the third quarter of this year and pivotal trials planned for next year, aiming for drug approval by 2028. The company focuses on preclinical translational research and aims to bring new drugs into phase I/II clinical trials for early authorization. With major shareholders such as Taiwan Cement, Fubon Financial, and others, Anji plans to apply for listing on the main board by 2025. Their product line includes the Kennedy Disease treatment drug AJ201, where last year, European and American development and commercialization rights were licensed to Nasdaq-listed Avenue for $250 million, with positive prospects for regional authorization and multi-center clinical trials in the future.
Source: YAHOO